Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
October 02, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
September 30, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
September 18, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
September 10, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
August 20, 2025 09:25 ET | Source: Greenwich LifeSciences, Inc.

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
August 19, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
August 13, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
August 11, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
April 03, 2025 08:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...